Future therapeutic options for celiac disease
- 1 March 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Gastroenterology & Hepatology
- Vol. 2 (3), 140-147
- https://doi.org/10.1038/ncpgasthep0111
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprueBiochemical Journal, 2004
- Coordinated Induction by IL15 of a TCR-Independent NKG2D Signaling Pathway Converts CTL into Lymphokine-Activated Killer Cells in Celiac DiseaseImmunity, 2004
- Prolyl Endopeptidase-Mediated Destruction of T Cell Epitopes in Whole Gluten: Chemical and Immunological CharacterizationThe Journal of pharmacology and experimental therapeutics, 2004
- A Direct Role for NKG2D/MICA Interaction in Villous Atrophy during Celiac DiseaseImmunity, 2004
- Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s diseaseGastroenterology, 2004
- Characterization of cereal toxicity for celiac disease patients based on protein homology in grainsGastroenterology, 2003
- Identification and Characterization of Lactobacillus helveticus PepO2, an Endopeptidase with Post-Proline SpecificityApplied and Environmental Microbiology, 2003
- CD3-specific antibody-induced active tolerance: from bench to bedsideNature Reviews Immunology, 2003
- Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma.Gut, 1995
- Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidaseGene, 1994